Priya Palta

Priya Palta

Auto-generated profile, based on publicly available information

Priya Palta

Department of Neurology, University of North Carolina School of Medicine, Chapel Hill

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
NMNour Makarem
Nour Makarem
CGCharles A. German
Charles A. German
ZZZhanhao Zhang
Zhanhao Zhang
KDKeith M Diaz
Keith M Diaz
PPPriya Palta
Priya Palta
Ari ShechterAri Shechter
Ari Shechter
Background: Rest‐activity rhythms (RARs), a measure of circadian rhythmicity in the free‐living setting, are related to mortality risk, but evidence is limited on associations with cardiovascular disease (CVD) and its risk factors. Methods and Results: Participants included 4521 adults from the 2013 to 2014 National Health and Nutrition Examination Survey physical activity monitoring examination. Wrist‐worn ActiGraph GT3X+ data were used to estimate RARs. Multivariable logistic models evaluated associations of RARs with prevalent CVD, hypertension, obesity, and central adiposity. Participants (mean age, 49 years) in the highest versus lowest tertile of relative amplitude (greater circadian rhythmicity) had 39% to 62% lower odds of prevalent CVD, hypertension, obesity, and central adiposity. A more active wake period was associated with 19% to 72% lower CVD, hypertension, obesity, and central adiposity odds. Higher interdaily stability (regular sleep‐wake and rest‐activity patterns) was related to 52% and 23% lower CVD and obesity odds, respectively. In contrast, participants in the highest versus lowest tertile of intradaily variability (fragmented RAR and inefficient sleep) had >3‐fold and 24% higher CVD and obesity odds, respectively. A later and less restful sleep period was associated with 36% to 2‐fold higher CVD, hypertension, obesity, and central adiposity odds. A statistically significant linear trend was observed for all associations ( P ‐trend<0.05). Conclusions: A robust, stable, and less fragmented RAR, an active wake period, and an earlier and more restful sleep period are associated with lower prevalent CVD, hypertension, obesity, and central adiposity, with evidence of a dose‐response relationship. The magnitude, timing, and regularity of sleep‐wake and rest‐activity patterns may be important targets for reducing cardiovascular risk.

14 May 2024 in Neurology
Verified
Journal Article
Closed access
MAMadeline Wood Alexander
Madeline Wood Alexander
CWChe-Yuan Wu
Che-Yuan Wu
GCGillian T. Coughlan
Gillian T. Coughlan
TPTanvi Puri
Tanvi Puri
RBRachel F. Buckley
Rachel F. Buckley
RJRabin Jennifer
Rabin Jennifer
Mounting evidence supports sex differences in Alzheimer disease (AD) risk. Vascular and hormonal factors may together contribute to AD risk in female adults. We investigated whether age at menopause, vascular risk, and history of hormone therapy (HT) containing estrogens together influence cognition over a 3-year follow-up period. We hypothesized that earlier menopause and elevated vascular risk would have a synergistic association with lower cognitive scores at follow-up and that HT containing estrogens would attenuate this synergistic association to preserve cognition. We used data from postmenopausal female participants and age-matched male participants in the Canadian Longitudinal Study on Aging. Vascular risk was calculated using a summary score of elevated blood pressure, antihypertensive medications, elevated low-density lipoprotein cholesterol, diabetes, smoking, and obesity. Cognition was measured with a global cognitive composite at baseline and 3-year follow-up. Linear models tested independent and interactive associations of age at menopause, vascular risk, and HT history with cognition at 3-year follow-up, adjusting for baseline cognition, baseline age, years of education, and test language (English/French). We included 8,360 postmenopausal female participants (mean age at baseline = 65.0 ± 8.53 years, mean age at menopause = 50.1 ± 4.62 years) and 8,360 age-matched male participants for comparison. There was an interaction between age at menopause and vascular risk, such that earlier menopause and higher vascular risk were synergistically associated with lower cognitive scores at follow-up (β = 0.013, 95% CI 0.001-0.025, p = 0.03). In stratified analyses, vascular risk was associated with lower cognitive scores in female participants with earlier menopause (menopausal ages 35-48 years; β = -0.044, 95% CI -0.066 to -0.022, p < 0.001), but not average (ages 49-52 years; β = -0.007, 95% CI -0.027 to 0.012, p = 0.46) or later menopause (ages 53-65 years; β = 0.003, 95% CI -0.020 to 0.025, p = 0.82). The negative association of vascular risk with cognition in female participants with earlier menopause was stronger than the equivalent association in age-matched male participants. HT history did not further modify the synergistic association of age at menopause and vascular risk with follow-up cognition (β = -0.005, 95% CI -0.032 to 0.021, p = 0.69). Endocrine and vascular processes may synergistically contribute to increased risk of cognitive decline in female adults. These findings have implications for the development of sex-specific dementia prevention strategies.

9 April 2024 in Neurology
Verified
Journal Article
Closed access
YLYifei Lu
Yifei Lu
JPJames R. Pike
James R. Pike
RHRon Hoogeveen
Ron Hoogeveen
KWKeenan Walker
Keenan Walker
LRLaura Raffield
Laura Raffield
PPPriya Palta
Priya Palta
Background and ObjectivesProspective measures of plasma and cerebral MRI biomarkers of Alzheimer disease (AD) and vascular neuropathology provide an opportunity to investigate possible mechanisms linking liver disease and dementia. We aimed to quantify ...

10 June 2025 in Neurology
Verified
Journal Article
Closed access
SSSrishti Shrestha
Srishti Shrestha
XZXiaoqian Zhu
Xiaoqian Zhu
MGMichael E. Griswold
Michael E. Griswold
PPPriya Palta
Priya Palta
KSKevin J. Sullivan
Kevin J. Sullivan
VKVidyulata Kamath
Vidyulata Kamath
Investigation of olfactory impairment, an early manifestation of Alzheimer disease (AD), in relation to plasma biomarkers of AD and neurodegeneration could provide insights into the disease's pathophysiology. Because few such studies based on large, diverse, community-based populations exist, we investigated associations of odor identification ability with plasma biomarkers of AD and other neurodegenerative pathologies in community-dwelling Black and White older adults. This cross-sectional investigation included participants from the Atherosclerosis Risk in Communities study who attended visit 5 (2011-2013) and who completed olfactory testing and brain MRI examinations and had plasma biomarkers measured (namely, amyloid-beta [Aβ]42/Aβ40 ratio, phosphorylated-tau at threonine-181 [p-tau181], p-tau181/Aβ42 ratio, glial fibrillary acidic protein [GFAP], and neurofilament light chain [NfL]). Odor identification ability was measured by the 12-item Sniffin' Sticks test. Separate linear regression models were used to examine the association of continuous olfaction score and olfaction categories (anosmia: score 6; hyposmia: 7-8; moderate-normal: 9-10; good-normal: 11-12) with each biomarker (all were log-transformed), adjusting for sociodemographic and cardiovascular factors, head injury, APOE-ε4 status, and estimated glomerular filtration rate. We further examined whether any observed associations are explained by total and regional brain volumes. Among 1,545 participants (age: 76 ± 5 years, 60% women, 27% self-reported Black participants), the mean olfaction score was 9.2 ± 2.3; 14% had anosmia. Consistent with our hypotheses, poorer olfactory scores were associated with higher plasma p-tau181 (β per 1-unit lower score: 0.026 [95% CI 0.012-0.040]), p-tau181/Aβ42 (β: 0.027 [95% CI 0.011- 0.044]), GFAP (β: 0.024 [95% CI 0.009-0.040]), and NfL (β: 0.034 [95% CI 0.019-0.050] and lower Aβ42/Aβ40 ratio (β: -0.007 [95% CI -0.015 to 0.000]). Likewise, compared with good-normal olfaction, anosmia showed associations with all biomarker levels indicative of greater neuropathology (e.g., β for plasma p-tau181/Aβ42: 0.235 [95% CI 0.113-0.358] and β for plasma NfL: 0.210 [95% CI 0.102-0.317]), although the association with Aβ42/Aβ40 ratio was not statistically significant (β: -0.054 [95% CI -0.108 to 0.001]). These biomarkers were not significantly associated with hyposmia or moderate-normal olfaction. Smaller medial-temporal lobe volumes partly explained olfaction's link with plasma p-tau181, p-tau181/Aβ42, GFAP, and NfL. Our findings suggest that poor olfaction is associated with multiple AD-related and other neurodegenerative processes. Future studies should investigate how longitudinal changes in both olfaction and biomarkers relate to each other.

13 May 2025 in Neurology
Verified
Journal Article
Closed access
ECEthan J. Cannon
Ethan J. Cannon
BWB. Gwen Windham
B. Gwen Windham
MGMichael Griswold
Michael Griswold
PPPriya Palta
Priya Palta
DKDavid S. Knopman
David S. Knopman
PLPamela Lutsey
Pamela Lutsey
Midlife obesity is a risk factor of dementia, but late-life obesity has been associated with lower dementia risk. We investigated this paradox by exploring the relationship between late-life body mass index (BMI) category and dementia, with and without considering midlife to late-life BMI change. This observational cohort study included participants of the community-based Atherosclerosis Risk in Communities (ARIC) study who were dementia-free at visit 5 (2011-2013). Dementia was ascertained by expert-adjudicated, algorithmic classification from an in-person neuropsychological battery, as well as telephone interviews and International Classification of Diseases codes from medical records. We first assessed the association of incident dementia with visit 5 BMI categories (normal weight, overweight, obese). Next, we used a cross-classification of visit 5 BMI categories with visit 4-visit 5 BMI change (decrease [loss of ≥2 kg/m2], increase [gain of ≥2 kg/m2], or stable [loss or gain of <2 kg/m2]) occurring during the 15 years before baseline. Cox regression was used. A total of 5,129 participants were included in the study (59% female; 22% identified as Black; mean (standard deviation) age at visit 5 of 75 (5) years). Over 8 years of follow-up, 20% of the sample developed dementia (n = 1,026). After covariate adjustment, participants with high late-life BMI had a lower risk of dementia; the hazard ratio (95% CI) was 0.86 (0.73-1.00) for overweight and 0.81 (0.68-0.96) for obesity. In stratified models, elevated dementia risk was observed only for participants of each late-life BMI category whose BMI had decreased from midlife to late life. Compared with normal-weight individuals who had maintained BMI from midlife to late life, the hazard ratio (95% CI) for those with BMI loss was 2.08 (1.62-2.67) for normal-weight individuals, 1.62 (1.25-2.10) for those with overweight, and 1.36 (1.00-1.85) for those with obesity. Our results provide insight into the dementia obesity paradox at older ages, tempering a causal interpretation of high late-life BMI as protective against dementia. Instead, they highlight the importance of considering weight loss from midlife to late life in conjunction with late-life BMI in dementia risk stratification.

27 January 2026 in Neurology
Verified
Journal Article
Closed access
WWWendy Wang
Wendy Wang
AWAmal A Wanigatunga
Amal A Wanigatunga
LELacey H. Etzkorn
Lacey H. Etzkorn
JRJill A. Rabinowitz
Jill A. Rabinowitz
PPPriya Palta
Priya Palta
LCLin Y. Chen
Lin Y. Chen
Aging is associated with changes in circadian rhythms. Rest-activity rhythms (RARs) measured using accelerometers are markers of circadian rhythms. Altered circadian rhythms may be risk factors of neurocognitive outcomes; however, results are mixed, and previous studies were often conducted in homogeneous populations. We aimed to assess the association between circadian RARs and incident dementia in a racially diverse sample of older adults. This was a retrospective examination of data from the Atherosclerosis Risk in Communities (ARIC) study, a community-based cohort study conducted at 4 US centers. ARIC participants who wore the Zio XT® long-term continuous monitoring patch in 2016-17 for ≥3 days and were free of prevalent dementia were included. RARs were derived from investigational accelerometer data from the patch. Nonparametric RARs included relative amplitude (rhythm strength), intradaily variability (rhythm fragmentation), and interdaily stability (rhythm consistency). Cosinor RARs included measures of rhythm strength (amplitude, mesor) and circadian timing (acrophase). Dementia cases were adjudicated through 2020 using in-person and phone assessments, hospitalization codes, and death certifications. Cox proportional hazards models were used. Of the 2,183 participants (mean ± SD age 79 ± 4.5 years, 58% female, 24% Black), 176 (8%) developed dementia. The median follow-up time was 3 years, and the mean Zio XT Patch wear time was 12 days. After multivariable adjustment, each 1-SD decrement in relative amplitude and 1-SD increment in intradaily variability were associated with 54% (95% CI 32%-78%) and 19% (95% CI 2%-38%) greater risk of dementia, respectively. Amplitude and mesor were associated with elevated dementia risk after multivariable adjustment (hazard ratios per 1-SD decrement: 1.43 [95% CI 1.15-1.78] and 1.33 [95% CI 1.08-1.63], respectively). A later acrophase was associated with 1.45 times (95% CI 1.01-2.07) greater risk of dementia compared with a normal acrophase. Using accelerometer data from a commonly used ambulatory ECG monitor, weaker and more fragmented circadian RARs and later peak activity time were prospectively associated with elevated dementia risk in older Black and White adults. Limitations of our study include the lack of dementia subtype data and objective sleep disorder measurements. Further research to determine whether circadian rhythm interventions can reduce dementia risk is warranted.